Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.56 |
| ▸ | WDR5 | P61964 | 5/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CCND3 | P30281 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564066 | 0.95 | LMNA (0.58) | CCNA2CDK2CCNA1SIRT6WDR5 | |
| SCHEMBL10127582 | 0.89 | SIRT6 (0.56) | CCNA2CDK2CCNA1SIRT6WDR5 | |
| SCHEMBL10036256 | 0.88 | WDR5 (0.49) | CCNA2CDK2CCNA1SIRT6WDR5 | |
| SCHEMBL22465912 | 0.87 | GAA (0.61) | ALDH1A1LMNAGAAHTTCYP1A2 | |
| SCHEMBL29378218 | 0.87 | GAA (0.61) | ALDH1A1LMNAGAAHTTCYP1A2 | |
| SCHEMBL15687873 | 0.85 | ALDH1A1 (0.59) | CCNA2CDK2CCNA1WDR5ALDH1A1 | |
| SCHEMBL28901655 | 0.84 | SLC6A9 (0.48) | CCNA2CDK2CCNA1WDR5ALDH1A1 | |
| SCHEMBL23538890 | 0.83 | ALDH1A1 (0.68) | CCNA2CDK2CCNA1WDR5ALDH1A1 | |
| SCHEMBL4150695 | 0.83 | SLC6A9 (0.47) | CCNA2CDK2CCNA1PIM1CDK4 | |
| SCHEMBL3212217 | 0.83 | SLC6A9 (0.64) | ALDH1A1LMNAHTTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104496940-A | Method for preparing BCR-ABL inhibitor intermediate | GUANGDONG HEC PHARMACEUTICAL | 2015-04-08 | — | — | CN | claimed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4161651-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-109369671-B | Fused tricyclic ureas as Raf kinase and/or Raf kinase dimer inhibitors | 百济神州有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-112601752-A | Novel inhibitors of MAP4K1 | 伊克诺斯科学公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3630778-A1 | NOVEL INHIBITORS OF MAP4K1 | Ichnos Sciences SA (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2020-02-18 | — | — | US | disclosed |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2020-02-18 | — | — | US | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| CN-1976938-A | Thienopyrazole derivatives having PDE7 inhibitory activity | ASUBIO PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | disclosed |
| EP-1551813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032882-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142437-A1 | CHEMICAL COMPOUNDS | CDK4, CDK2, CDK3 | CCNA2 42/4885CDK2 2/4885CCNA1 45/4885 |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | HCK, BTK, LYN | CCNA2 3616/4885CDK2 393/4885CCNA1 2646/4885 |
| US-20050288515-A1 | Chemical compounds | CDK4, CDK2, CDK3 | CCNA2 42/4885CDK2 2/4885CCNA1 45/4885 |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | CCNA2 991/4885CDK2 27/4885CCNA1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.